INCB039110

DRUG3 trials

Sponsors

Incyte Corporation, Washington University School of Medicine, Massachusetts General Hospital

Conditions

Advanced MalignanciesMelanomaMetastatic CancerPruritisSolid Tumors

Phase 1

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

TerminatedNCT02265510

Incyte CorporationAdvanced Malignancies, Metastatic Cancer, Solid Tumors

Start: 2014-09-10End: 2019-02-27Updated: 2020-04-17

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

TerminatedNCT03272464

Massachusetts General HospitalMelanoma

Start: 2019-05-29End: 2019-12-27Updated: 2023-09-22

Phase 2

Relieving Chronic Itch: Oral Medication

WithdrawnNCT02909569

Washington University School of MedicinePruritis

Start: 2018-08-31End: 2018-10-09Updated: 2019-05-13

Related Papers

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus <i>nab</i>-Paclitaxel and Gemcitabine in Advanced Solid Tumors

The Oncologist2018-08-1643 citations